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Background: This study was designed to address the concern that intensive regimens to eradicate early Pseudomonas aeruginosa infection in
patients with cystic fibrosis may lead to the emergence of antibiotic-resistant isolates.
Methods: Data was analysed retrospectively over a 10 year period at the Leeds Regional Paediatric Cystic Fibrosis Centre. All patients with first-
ever isolation of P. aeruginosa who successfully completed an eradication regimen were included. Antibiotic sensitivities of P. aeruginosa were
compared between initial and subsequent re-isolations in patients where eradication was successful and in those where treatment had failed.
Results: Forty one patients with first acquisitions for P. aeruginosa and who completed eradication treatment were identified. Eradication
treatments consisted of oral, intravenous, nebulised antibiotics or a combination of these. The antibiotic sensitivity of P. aeruginosa in first
growths was high and remained so on subsequent re-isolations. A repeated measures logistic model found no significant difference with time of
isolation. There was no statistically significant difference in antibiotic sensitivity between P. aeruginosa isolated after successful and failed
eradication.
Conclusions: Repeated intensive regimens for P. aeruginosa eradication did not result in a significant increase in overall antibiotic resistance
between initial and subsequent growths of this organism over the period of this study.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Pseudomonas aeruginosa; Eradication; Antibiotic resistance1. Introduction
Chronic pulmonary infection with Pseudomonas aeruginosa
in patients with cystic fibrosis (CF) is associated with an
increased rate of decline in respiratory function [1,2] and
increased morbidity and mortality [3,4]. It is not possible to
eradicate chronic P. aeruginosa infection [5] but early intensive
antibiotic treatment of new isolates of P. aeruginosa can delay
the onset of chronic infection [6–8]. Although some of the latter
studies have been criticised for being retrospective, small, or for
using historical controls [9], two small prospective randomised⁎ Corresponding author. Department of Paediatrics, Macclesfield General
Hospital, Victoria Road, Macclesfield, Cheshire, SK10 3BL, UK. Tel.: +44 1625
661755; fax: +44 1625 661052.
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doi:10.1016/j.jcf.2008.08.001placebo-controlled trials of antibiotic eradication regimens for
early P. aeruginosa pulmonary infection have demonstrated
significantly better clearance of the organism from the airway
using nebulised tobramycin preparations when compared to
placebo [10,11]. These studies were not able to assess whether
eradication therapy delayed the onset of chronic P. aeruginosa
infection. These perceived limitations in the evidence for the
efficacy of eradication therapy against early P. aeruginosa
infection, together with concerns regarding the risks of
encouraging the emergence of resistant strains of P. aeruginosa
[12,13], has limited the implementation of such regimens,
particularly in the USA [12]. Studies that have investigated the
emergence of antibiotic-resistant isolates have concentrated on
prolonged antibiotic use in patients known to be chronically
infected with P. aeruginosa [14–20]. If attempted eradication
regimens merely suppress P. aeruginosa growth one mightd by Elsevier B.V. All rights reserved.
Table 1





















No. of patients, n (%) 12 (11.1) 41 (38.0) 5 (4.6) 9 (8.3) 15 (13.9) 4 (3.7) 10 (9.3) 4 (3.7) 8 (7.4)
Table 2
Number, n (%), susceptible P. aeruginosa isolates to individual antibiotics, time







Piperacillin 39 (86.7) 39 (79.6) 22 (88.0)
Tobramycin 41 (91.1) 42 (85.7) 25 (100)
Ciprofloxacin 42 (93.3) 40 (81.6) 23 (92.0)
Ceftazidime 43 (95.6) 44 (88.0) 25 (100)
Amikacin 40 (88.9) 42 (85.7) 25 (100)
Colistin 44 (97.8) 46 (93.9) 25 (100)
Sensitivity of isolates to
all antibiotics
35 (77.8) 31 (63.3) 21 (84.0)
Time (days) to next isolation of







44 S.A. Ho et al. / Journal of Cystic Fibrosis 8 (2009) 43–46expect to see an increase in antibiotic resistance in isolates from
patients after they have received eradication treatment. The aim
of this study was to determine if antibiotic treatment to eradicate
early isolates of P. aeruginosa led to the emergence of resistant
strains of this bacterium.
2. Methods
Patients were categorised according to the definition of
Pseudomonas status described by Lee et al. [21]. Patients with
first acquisitions were defined as those who had previously
never grown P. aeruginosa from respiratory tract samples.
Patients were described as free of infection if they had previously
grown P. aeruginosa and received an eradication regimen and
then became culture-negative for P. aeruginosa infection on all
subsequent sputum or cough swab specimens for at least
12 months. Failed eradication was defined as re-isolation of
P. aeruginosa in patients within 12 months of completing treat-
ment for P. aeruginosa eradication. Inclusion criteria were
patients with first acquisitions of P. aeruginosa, those who
subsequently became free of infection after receiving an
eradication regimen and those who failed eradication having
been previously free of infection immediately prior to the
episode of infection being treated. The P. aeruginosa status of all
patients receiving full-time care at the Leeds Regional Paediatric
CF Centre from January 1990 to December 2000 was retro-
spectively determined. Patients had been diagnosed on the basis
of a positive sweat test and/or genotyping. The children were
reviewed at four to six weekly intervals. Sputum or cough swab
specimens were taken at each clinic visit.
P. aeruginosa was isolated from respiratory samples using
routine microbiological methods. Antimicrobial sensitivity was
determined using Stokes' comparative disk diffusion method.
All isolates were tested on lysed blood agar and compared
against a fully-susceptible control strain of P. aeruginosa after
48 h incubation at 37 °C in air.
Demographic data, antibiotic sensitivities, and P. aeruginosa
eradication regimens used were obtained from case records.
Sensitivities to the six most consistently used antibiotics (cipro-
floxacin, piperacillin, tobramycin, ceftazidime, amikacin and
colistin) were analysed for all first and subsequent re-isolations
of P. aeruginosa.
2.1. Statistical analyses
Data were analysed by a repeated measures logistic model to
take into account the repeated nature of the measurements.
McNemar's test was used to compare antibiotic sensitivities in
P. aeruginosa isolated from patients in whom eradicationtreatment had initially failed but who later became free of
infection following more intense treatment. In addition, the
overall antibiotic resistance of P. aeruginosa isolates from first
acquisitions were compared with subsequent isolates obtained
from the same patients after they had been free of infection
(as defined by Lee et al.) following an eradication regimen. A
P valueb0.05 was taken to indicate significance.
3. Results
Forty one patients (23 males) were identified with first
acquisitions of P. aeruginosa who following eradication treat-
ment remained free of infection for at least 12 months. Their
median age was 2.80 (range 0.25 to 12.56) years. The antibiotic
sensitivities of newly acquired isolates were analysed from
these patients. In four patients two phenotypes of P. aeruginosa
were isolated from the same sputum/cough swab specimen.
Almost all (95.5%) of first P. aeruginosa isolates were non-
mucoid. The combination of antibiotics used for eradication
regimens was varied and are shown in Table 1. The antibiotic-
susceptibility of each isolate to the six antibiotics was deter-
mined for initial and further 2 subsequent isolates (first and
second) of P. aeruginosa and are shown in Table 2. Forty one
patients (49 isolates) had one re-isolation of P. aeruginosa
(in eight patients two phenotypes were isolated from the same
sputum or cough swab sample). Nineteen patients (25 isolates)
had a second re-isolation (in two patients two phenotypes and in
two other patients three phenotypes were isolated from the same
sputum or cough swab sample).
A repeated measures logistic model showed no significant
increase in antibiotic resistance of P. aeruginosa with time of
isolation. McNemar's test showed there was no significant
difference between patients in terms of antibiotic resistance in
P. aeruginosa isolates in whom eradication was successful and
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sensitive isolates on initial and subsequent re-isolations to all 6
antibiotics also remained high and is shown in Table 2.
3.1. Failed eradication
Forty seven isolates of P. aeruginosa were identified where
eradication treatment had initially failed. The antibiotic resis-
tance was compared between isolates prior to treatment and
those grown after completion of the failed eradication regimen.
For each of the 6 antimicrobials the antibiotic sensitivity of all
P. aeruginosa isolates remained high (≥75.0% of all isolates
were fully-sensitive). McNemar's test showed there was evi-
dence of increasing resistance for one antibiotic (ceftazidime,
P value 0.016 not corrected for number of tests: with correction
0.096). A paired-t-test showed that there was no overall evi-
dence for change in sensitivity collectively for all 6 antibiotics
(t=0.33, P value 0.74, confidence interval for difference −0.32
to 0.45). This analysis did not take account of the fact some
patients occurred more than once. Using a “mixed model” to
allow for this also showed no significant change in score
(P value 0.84, 95% confidence interval −0.66 to 0.54). In
summary, 2 statistical models showed there was no overall
change in sensitivity and there was evidence of increasing
resistance for one antibiotic (ceftazidime). However, that should
be treated with caution in view of the number of tests and the
lack of overall significance with the paired-t-test and mixed
model.
4. Discussion
This study describes the antibiotic sensitivity of first and
subsequent isolations of P. aeruginosa from children with CF
when intensive early eradication regimens have been used.
There were no significant differences in the antibiotic sensitivity
of P. aeruginosa to six commonly prescribed antibiotics for first
and subsequent acquisitions despite the use of intensive anti-
biotic regimens in attempts to eradicate the infection. The
overall antimicrobial resistance of newly acquired P. aeruginosa
was generally low in contrast to the study of Pitt et al. which
showed a high level of resistance of all P. aeruginosa infection
(new acquisitions and chronic) from UK patients with CF to
commonly used anti-pseudomonal agents [13]. Pitt et al. found
62% of all isolates were resistant to one or more antibiotics.
Using pulsed field gel electrophoresis two previous studies have
shown that the type of P. aeruginosa on re-isolation was
genotypically distinct from the initial infection which strongly
suggests that the initial eradication was successful and the new
growth was a new organism [22,23]. Persisting P. aeruginosa in
the lower airway would potentially show an increase in anti-
biotic resistance with time because of prolonged exposure to
antibiotics. Our study provides further evidence that eradication
regimens may be successful at completely eliminating
P. aeruginosa from the lower respiratory tract as we did not
demonstrate any significant increase in antibiotic resistance in
subsequent isolates of this organism after eradication treatment
was completed.P. aeruginosa acquired from the environment is usually non-
mucoid and highly antibiotic-susceptible [20]. A similar pattern
was observed in this study of newly acquired organisms where
95.5% of organisms were non-mucoid and over three-quarters
were fully-sensitive to tested antibiotics. In chronically infected
patients the resistance of P. aeruginosa has been shown to
increase with time [14,15,23,24]. This study supports the hy-
pothesis that the main source of infection for new acquisitions of
this organism is the environment rather than other patients.
There are several limitations to this study. The data was ana-
lysed retrospectively. The number of patients included was rela-
tively small particularly in re-isolations and therefore a statistically
significant difference may not have been detected (type 2 error).
Genotyping of P. aeruginosa strains was not performed and
therefore it was not possible to be absolutely sure if subsequent re-
isolations of P. aeruginosa were new environmental strains or the
original organism. Minimum inhibitory concentrations (MIC's)
were not performed. The method for analysing antibiotic sen-
sitivities was Stoke's disk diffusionwhich is essentially qualitative
rather than quantitative. Qualitative results may have suggested
no change in resistance with time when there may have actually
been a change in susceptibility with an increase in MIC's.
Optimal management of new P. aeruginosa infection involves
early and prolonged use of systemic and nebulised antibiotics. The
standard treatment for eradicating new isolates ofP. aeruginosa is
twice daily oral ciprofloxacin and nebulised colistin for 3 months
[7]. Over the last decade no new oral anti-pseudomonal drugs,
apart from other quinolones, have become available. This raises
concern because of the risk of increasing drug resistance to
existing anti-pseudomonal agents that are used extensively.
However, this study showed that antibiotic resistance in
subsequent isolates of P. aeruginosa had not increased following
attempted eradication treatment of earlier infection. The antibiotic
sensitivity of subsequent isolates remained high in patients who
initially acquired the organism and who were managed with
systemic and nebulised antibiotics. This study provides evidence
that early aggressive eradication regimens for P. aeruginosa in
cystic fibrosis does not promote drug resistance in this organism.
However, further studies are warranted to allay concerns of
emerging resistance in this group of patients.
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